Frequently Asked Questions: Everything You Need to Know About Demeetra’s Gene Editing Platforms and Licensing
Demeetra: Commercial & Licensing FAQs
Yes. Clients typically begin with a low-cost evaluation license, which includes three vials of Cas-CLOVER, protocols, and technical support. This grants a 6-month trial period to evaluate the technology before pursuing a full commercial license.
Not for commercial cell line development and bioprocessing. Demeetra’s licensing model is designed for simplicity: Cas-CLOVER can be licensed with one-time fees and no ongoing royalties or milestones, offering superior commercial freedom compared to CRISPR/Cas9 systems.
After the evaluation period, clients execute a full license, which typically involves a one-time fee or multi-year fee, depending on the application and scope.
Demeetra provides comprehensive support, including technical onboarding, gRNA and construct design guidance, and access to a full set of internally developed and externally validated protocols. Our team of bench scientists, who work hands-on with Cas-CLOVER, Harbor-IN and CleanCut CHO daily—deliver presentations, detailed troubleshooting, and expert guidance to ensure a smooth and successful evaluation.
If the evaluation is successful, Demeetra will support the transition to a full commercial license, managed directly by our CEO and licensing team. This enables ongoing commercial and research use of Cas-CLOVER for cell line development and bioprocessing applications.
If the partner chooses not to proceed with a full license, they are required to discontinue use of the technology, including any cells or materials generated using Cas-CLOVER during the evaluation.
Yes. Cas-CLOVER offers robust FTO for commercial use, as it operates independently from Cas-based editing. Unlike CRISPR/Cas9, genome editing with Cas-CLOVER is performed by a dimeric nuclease, Clo051, not by Cas9 or any other Cas enzyme. The system is guided to the target site by two gRNAs complexed with a nuclease-inactive dCas9, which binds DNA without introducing cuts.
Demeetra has secured comprehensive licensing for all components of the Cas-CLOVER system, including:
- Guide RNAs and dCas9: licensed from ERS Genomics (covering the California, Vienna, Charpentier “CVC” IP portfolio),
- Clo051 nuclease: licensed from Helmholtz Munich,
- Cas-CLOVER composition and use: licensed from Poseida Therapeutics,
- Plus Demeetra’s own patents covering proprietary improvements to Clo051.
This unique, bundled licensing framework provides clients with exceptional FTO and commercial clarity, setting Cas-CLOVER apart from traditional CRISPR/Cas systems.
The answer lies in cost, simplicity, clarity, and reduced diligence burden Using CRISPR/Cas9 or other Cas-based systems requires navigating a complex intellectual property landscape, around 20,000 patents and more than 500 individual applicants, which significantly complicates licensing and FTO evaluations.
In contrast, Cas-CLOVER offers a streamlined path. The system involves just three core IP holders —all of whom are already licensed by Demeetra. This bundled, transparent licensing approach minimizes due diligence and provides clear, consolidated FTO for commercial use.
While we can’t speak to the exact costs of CRISPR/Cas9 licenses, commercial use often involves securing multiple agreements from different IP holders—many of which include annual fees, milestone payments, and stacked royalties. This can create complexity and escalating costs as projects scale.
In contrast, Cas-CLOVER is offered under a straightforward, one-time fee, providing clear, predictable costs. This structure is designed to scale with your innovation—not against it, making it an attractive option for commercial biomanufacturing.
Yes. Demeetra’s license allows transfer of Cas-CLOVER to CROs, CDMOs, and academic collaborators, provided they are working exclusively on behalf of the licensee.
Yes. Cas-CLOVER licensees retain full rights to all downstream results, including gene edits, cell lines, and methods developed using the technology. Demeetra only retains rights to the core gene editing components, specifically the Cas-CLOVER sequences and any direct modifications to those sequences.
Yes. Harbor-IN is sold as a commercial reagent, with full commercial or research use rights included in the product purchase. No separate license is required.
Yes. The CleanCut CHO platform is available for pre-GMP research use under an annual fee. When you are ready to scale to GMP manufacturing and commercial production, expanded use rights are available, and economic and key terms can be shared following execution of a confidentiality agreement.
Transfer of non-engineered CleanCut CHO platform cells is not permitted. However, the transfer of engineered, stable cell lines generated on the CleanCut CHO platform is straightforward and cost-effective. Applicable transfer rights and conditions are defined in the purchase agreement.
No. There are no media restrictions on the CleanCut CHO platform. The cells are compatible with a variety of commercial media, and have been shown to adapt well to several formulations, including CD FortiCHO.
Demeetra: Gene Editing Tools Technical FAQs
Yes. Demeetra continuously validates and optimizes its core technologies and workflows. We provide partners with detailed protocols covering every stage of the gene editing process—including guide RNA design, transposon vector cloning, transfection, editing validation, selection, and single-cell cloning. Comprehensive technical support is included to ensure efficient tech transfer and successful outcomes.
Cas-CLOVER uses a fusion of dCas9 (binding only, no cutting) and Clo051 (cutting domain). Two guides are required to position the dimer properly, enabling the Clo051 domains to dimerize and cut DNA. This results in precise double-stranded breaks with sticky ends, which enhances knock-in efficiency.
Cas-CLOVER demonstrates comparable knockout (KO) efficiency to Cas9 and higher targeted integration or knock-in (KI) efficiency, particularly for larger cargos. It uses a dimeric Clo051 nuclease and two guide RNAs, resulting in 4 bp overhangs for staggered cuts. This enables larger deletions and significantly fewer off-target effects and chromosomal translocations than Cas9.
Cas-CLOVER requires a pair of guide RNAs spaced 11–31 base pairs apart in a PAM-out orientation. Optimal cutting is typically achieved with spacers in the 16–25 bp range. This broad and flexible spacing makes it easier to identify effective gRNA pairs—we have never encountered a gene that couldn’t be targeted.
For design, we recommend using CRISPOR or CHOPCHOP to identify candidate guides. Demeetra can provide automated design templates and technical assistance to help partners select optimal gRNA pairs. These are then validated experimentally, often using T7 Endonuclease I assays, to confirm cutting efficiency in parallel or before proceeding with gene editing projects.
Demeetra does not supply gRNAs directly. We provide the codon-optimized Cas-CLOVER mRNA, patent rights, and know-how transfer, along with comprehensive support for guide design. This includes automated design templates and technical assistance to help partners select optimal gRNA pairs. For synthesis, we recommend ordering 2-part chemically modified gRNAs from trusted providers such as Integrated DNA Technologies (IDT) or GenScript.
Cas-CLOVER routinely enables targeted integrations of 10 kb or larger, often with higher efficiency than CRISPR/Cas9. This capability makes it especially well-suited for applications requiring stable integration into safe harbor sites or genomic hotspots, such as cell line development, landing pad creation, and complex multi-gene constructs.
Yes. Cas-CLOVER supports efficient multiplexed gene editing. In CHO cells, we have successfully targeted three genes simultaneously, and in plants, we have edited four genes and up to 16 alleles in a single experiment. The multiplexing capability of Cas-CLOVER is especially useful for eliminating problematic host cell proteins (HCPs) from the process. The system’s dimeric design and high specificity make it well-suited for complex, multi-target applications without increasing off-target risk.
GUIDE-seq studies have shown that Cas-CLOVER exhibits extremely low off-target activity, with average indel rates ranging from just 0.012% to 0.089%, and minimal chromosomal rearrangements. This is in stark contrast to CRISPR/Cas9, which can exhibit off-target rates in CHO cells of 10% or more and translocation rates as high as 7%. In a recent CleanCut GS CHO whole genome sequencing (WGS) analysis conducted by Demeetra, we evaluated the top 10 predicted off-target sites per gRNA and detected no off-target mutations, further validating Cas-CLOVER’s exceptional precision.
Harbor-IN transposase is an optimized mRNA with a distinct sequence from Super piggyBac, designed specifically for efficient gene integration in bioproduction-relevant mammalian cells such as CHO and HEK293. Like Super piggyBac, it targets TTAA motifs in open chromatin regions, favoring stable, high-expression integration profiles. Unlike Super piggyBac, Harbor-IN is offered license-free, making it ideal for commercial cell line development use without downstream restrictions.
Cas-CLOVER and Harbor-IN transposase are optimized for CHO cell engineering in bioproduction workflows. Cas-CLOVER enables precise, disruptive, multiplexable gene knockouts and high-efficiency knock-ins at defined genomic loci, supporting rapid development of high-producing clones. Harbor-IN, a license-free transposase, stably integrates transgenes into transcriptionally active regions, driving high titers industry-leading productivity in combination with Cas-CLOVER-edited CleanCut CHO lines. Together, these technologies deliver ideal solutions for commercial biologics manufacturing.
The CleanCut CHO platform is based on CHO-K1 cells originally sourced from the European Collection of Authenticated Cell Cultures (ECACC). These cells were first adapted from adherent to suspension culture, and an optimal clone was selected based on key parameters such as doubling time and growth characteristics prior to gene editing. This ensures a robust and scalable foundation for high-performance bioproduction.
Does Demeetra provide a full cell line history and viral testing data for the CleanCut CHO platform?
Yes. Demeetra maintains a comprehensive cell line history report for CleanCut CHO, detailing the process from vial thaw through master cell bank (MCB) freeze-down. The platform has undergone rigorous quality testing, including mycoplasma, sterility, and two independent viral panels performed by IDEXX and Charles River Laboratories, all of which returned clean results.
CleanCut GS CHO cells were engineered using Cas-CLOVER, enabling precise, high-efficiency knockout of the Glutamine Synthetase (GS) gene with minimal off-target risk, ensuring greater genomic stability in production clones. Unlike traditional GS knockout approaches, CleanCut also targets a previously unrecognized GS homologue on Chromosome 1, in addition to the well-known GS gene on Chromosome 5. This dual knockout enhances selection stringency and consistently yields higher-producing clones, making CleanCut a superior platform for commercial biologics manufacturing.
Yes. In a stability study using CleanCut GS CHO cells, Trastuzumab was stably integrated using the Harbor-IN transposase. Expression remained stable over 60 generations in both bulk pools and a selected monoclonal line. There was no loss in titer or productivity in the bulk pools, and the clone was also proven to be stable. This confirms that Harbor-IN supports long-term, high-level expression suitable for commercial bioproduction. The stability of the bulk pools suggests that IND-enabling and Phase I material may be produced in pools, speeding up times to the clinic.
Using Demeetra’s optimized protocols, Harbor-IN transposase typically achieves 5 to 12 integration copies per cell in CHO systems, as measured by digital PCR (dPCR). This consistent range supports strong and stable expression, making Harbor-IN ideal for cell line development and bioproduction applications.
Harbor-IN transposons can support stable integration of large and complex DNA cargos, routinely handling constructs over 20 kb with a maximum of 200 kb achieved in-house. Therefore, Harbor-IN can be used to deliver and stably express bi-specific (bsAb) and tri-specific antibody constructs in CHO cells. This makes Harbor-IN well-suited for advanced therapeutic protein production, including next-generation biologics with complex architectures.
When cloning a gene of interest (GOI) into Demeetra’s transposons for use with Harbor-IN transposase, it is critical to preserve the integrity of the core transposon elements and maintain optimal spacing for robust expression and stable integration:
- Keep core elements intact: Do not modify or remove the inverted terminal repeats (ITRs) or core insulators, as they are essential for transposition and transgene stability.
- Maintain spacing from core insulators: Leave at least 100 bp of spacer sequence between each core insulator and the nearest promoter or coding sequence. This helps maintain insulator function and consistent expression.
- Stay within the ITRs: Only elements located between the ITRs will be integrated into the host genome. Any sequence outside the ITRs (in the plasmid backbone) will be excluded.
- PCR caution: Avoid PCR amplification from ITR to ITR, as the hairpin structure can cause aberrant amplification products (~600–750 bp).
These principles apply to all transposons supplied by Demeetra, regardless of the specific vector used.
Yes. All components within Demeetra’s transposon systems—including promoters, insulators, selection markers, and vector backbones are either in the public domain or otherwise fully cleared for commercial use. This ensures complete freedom to operate (FTO), with no licensing restrictions or downstream royalty obligations for research, development, or commercial manufacturing.
Yes. Demeetra has successfully produced afucosylated Trastuzumab using its CleanCut GS ADCC+ CHO cells, which combine the GS double knockout with a Fut8 knockout. This engineered cell line enhances antibody-dependent cellular cytotoxicity (ADCC), making it ideal for developing next-generation therapeutic antibodies.
Yes. Cas-CLOVER can knock out selection genes (like GS), or other important targets such as host cell proteins (HCPs) while Harbor-IN integrates the gene of interest. This combination is used in Demeetra’s CleanCut CHO GS cell platform for efficient selection and high expression levels (>8 g/L titers).
Demeetra provides integrated genome engineering platforms, and products, backed by deep technical expertise.
Contact us to learn how our differentiated IP, flexible access models, and internal know-how can support adoption from discovery through bioprocessing and commercial use.